J&J 10-Q: Debt Maturities and Financial Snapshot

Ticker: JNJ · Form: 10-Q · Filed: 2025-04-23T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, debt, financials

TL;DR

JNJ 10-Q out: Lots of debt notes maturing between 2028-2055. Financials look stable.

AI Summary

Johnson & Johnson filed its 10-Q for the period ending March 30, 2025. The filing details the company's financial position, including various debt instruments such as notes due in 2028, 2029, 2032, 2033, 2035, 2036, 2037, 2044, 2045, and 2055. It also references retained earnings and accumulated other comprehensive income as of December 29, 2024.

Why It Matters

This filing provides insight into Johnson & Johnson's debt structure and financial health, which can influence investor confidence and the company's ability to fund future operations and growth.

Risk Assessment

Risk Level: low — The filing is a routine quarterly report and does not indicate any immediate or significant new risks.

Key Numbers

2025-03-30 — Reporting Period End Date (Quarterly financial data is reported as of this date.)
2024-12-29 — Previous Year End Date (Comparative financial data from the prior fiscal year end.)

Key Players & Entities

JOHNSON & JOHNSON (company) — Filer
20250330 (date) — Period of Report
20250423 (date) — Filing Date
2024-12-29 (date) — Previous Fiscal Year End
2028 (date) — Debt Maturity Year
2055 (date) — Debt Maturity Year

FAQ

What is the total value of the debt instruments listed in the filing?

The filing lists various debt notes with specific maturity dates (e.g., November 2028, February 2029, June 2032, etc.) but does not provide a consolidated total dollar amount for all outstanding debt in this excerpt.

What is the fiscal year end for Johnson & Johnson?

Johnson & Johnson's fiscal year ends on December 28.

What is the primary industry classification for Johnson & Johnson?

Johnson & Johnson is classified under 'Pharmaceutical Preparations' with the SIC code 2834.

What are some of the specific debt instruments mentioned?

The filing mentions notes due November 2028 (A1.150%), February 2029 (A2.700%), June 2032 (A3.20%), February 2033 (A3.050%), 2035 (A1.650%), June 2036 (A3.350%), February 2037 (A3.350%), June 2044 (A3.550%), February 2045 (A3.600%), and February 2055 (A3.700%).

What is the filing date of this 10-Q report?

This 10-Q report was filed on April 23, 2025.

From the Filing

0000200406-25-000119.txt : 20250423 0000200406-25-000119.hdr.sgml : 20250423 20250423160445 ACCESSION NUMBER: 0000200406-25-000119 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20250330 FILED AS OF DATE: 20250423 DATE AS OF CHANGE: 20250423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 25861372 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 10-Q 1 jnj-20250330.htm 10-Q jnj-20250330 0000200406 12/28 2025 Q1 FALSE 33 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:EUR jnj:segment jnj:claimant jnj:cases 0000200406 2024-12-30 2025-03-30 0000200406 us-gaap:CommonStockMember 2024-12-30 2025-03-30 0000200406 jnj:A1.150NotesDueNovember2028Member 2024-12-30 2025-03-30 0000200406 jnj:A2.700NotesDueFebruary2029Member 2024-12-30 2025-03-30 0000200406 jnj:A3.20NotesDueJune2032Member 2024-12-30 2025-03-30 0000200406 jnj:A3.050NotesDueFebruary2033Member 2024-12-30 2025-03-30 0000200406 jnj:A1.650NotesDue2035Member 2024-12-30 2025-03-30 0000200406 jnj:A3.350NotesDueJune2036Member 2024-12-30 2025-03-30 0000200406 jnj:A3.350NotesDueFebruary2037Member 2024-12-30 2025-03-30 0000200406 jnj:A3.550NotesDueJune2044Member 2024-12-30 2025-03-30 0000200406 jnj:A3.600NotesDueFebruary2045Member 2024-12-30 2025-03-30 0000200406 jnj:A3.700NotesDueFebruary2055Member 2024-12-30 2025-03-30 0000200406 2025-04-18 0000200406 2025-03-30 0000200406 2024-12-29 0000200406 2024-01-01 2024-03-31 0000200406 us-gaap:RetainedEarningsMember 2024-12-29 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-29 0000200406 us-gaap:CommonStockMember 2024-12-29 0000200406 us-gaap:TreasuryStockCommonMember 2024-12-29 0000200406 us-gaap:RetainedEarningsMember 2024-12-30 2025-03-30 0000200406 us-gaap:TreasuryStockCommonMember 2024-12-30 2025-03-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-30 2025-03-30 0000200406 us-gaap:RetainedEarningsMember 2025-03-30 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-30 0000200406 us-gaap:CommonStockMember 2025-03-30 0000200406 us-gaap:TreasuryStockCommonMember 2025-03-30 0000200406 2023-12-31 0000200406 us-gaap:RetainedEarningsMember 2023-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000200406 us-gaap:CommonStockMember 2023-12-31 0000200406 us-gaap:TreasuryStockCommonMember 2023-12-31 0000200406 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000200406 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000200406 2024-03-31 0000200406 us-gaap:RetainedEarningsMember 2024-03-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000200406 us-gaap:CommonStockMember 2024-03-31 0000200406 us-gaap:TreasuryStockCommonMember 2024-03-31 0000200406 jnj:PatentsAndTrademarksMember 2025-03-30 0000200406 jnj:PatentsAndTrademarksMember 2024-12-29 0000200406 us-gaap:OtherIntangibleAssetsMember 2025-03-30 0000200406 us-gaap:OtherIntangibleAssetsMember 2024-12-29 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2025-03-30 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2024-12-29 0000200406 jnj:InnovativeMedicineMember 2024-12-29 0000200406 jnj:MedTechMember 2024-12-29 0000200406 jnj:InnovativeMedicineMember 2024-12-30 2025-03-30 0000200406 jnj:MedTechMember 2024-12-30 2025-03-30 0000200406 jnj:InnovativeMedicineMember 2025-03-30 0000200406 jnj:MedTechMember 2025-03-30 0000200406 us-gaap:ForeignExchangeCon